The main purpose of this study is to assess the bioequivalence (BE) of the fixed combination
of follitropin alfa and lutropin alfa in Pergoveris freeze-dried (FD) (Test 1) or in
Pergoveris Liquid (Test 2) versus the co-administration of Gonal-f and Luveris (Reference),
administered subcutaneously (SC) in pituitary suppressed, healthy premenopausal Chinese
female participants, at the doses of 900 international unit (IU) of follitropin alfa and 450
IU lutropin alfa.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany